MORPHOLOGICAL CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES (MDS) - COMBINED UTILIZATION OF BONE-MARROW ASPIRATES AND TREPHINE BIOPSIES

被引:51
作者
BARTL, R
FRISCH, B
BAUMGART, R
机构
[1] TEL AVIV UNIV, ICHILOV HOSP, INST HAEMATOL, IL-69978 TEL AVIV, ISRAEL
[2] UNIV MUNICH, KLINIKUM GROSSHADERN, MED KLIN 3, W-8000 MUNICH 70, GERMANY
关键词
BONE MARROW BIOPSY AND ASPIRATE; MYELODYSPLASTIC SYNDROMES; CLASSIFICATION; PROGNOSIS; EVOLUTION; EFFECTS OF THERAPY;
D O I
10.1016/0145-2126(92)90096-P
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a retrospective and prospective follow-up study from 1975 to 1991, bone marrow biopsies, aspirates and clinical features of 495 patients with MDS were investigated. Sections of undecalcified plastic embedded biopsies and smears of bone marrow aspirates were stained according to Giemsa. Bone marrows with MDS were characterized by three main categories of morphologic alterations: (1) cellular abnormalities, (2) architectural disorganization in the bone marrow and (3) stromal changes; the combined use of aspirates and trephine biopsies enabled a more reliable and accurate diagnosis of MDS than either one alone. The bone marrow findings fell into one of 7 subtypes, with the frequencies and median survivals in brackets: (1) MDS sideroblastic (19%, 62 months), (2) MDS megaloblastoid (13%, 56 months), (3) MDS proliferative (22%, 31 months), (4) MDS blastic (15%, 9 months), (5) MDS hypoplastic (15%, 26 months), (6) MDS fibrotic (6%, 29 months), and (7) MDS inflammatory (10%, 42 months). In follow-up studies patients with secondary MDS were excluded and the prognosis and subsequent evolution for each of the morphologic subtypes were evaluated. The conclusion is drawn that aspirates and trephine biopsies are complementary procedures and both are required for diagnosis, classification and decisions on current treatment modalities of patients with MDS.
引用
收藏
页码:15 / 33
页数:19
相关论文
共 36 条
[1]  
BAIN BJ, 1990, LEUKAEMIA DIAGNOSIS
[2]  
Bartl R, 1984, Bibl Haematol, P1
[3]   PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199
[4]   THE TREATMENT OF ANEMIA IN THE MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].
BOWEN, D ;
CULLIGAN, D ;
JACOBS, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (03) :419-423
[5]   HISTOPATHOLOGY OF MYELODYSPLASTIC SYNDROMES - THE FAB CLASSIFICATION (PROPOSALS) APPLIED TO BONE-MARROW BIOPSY [J].
DELACRETAZ, F ;
SCHMIDT, PM ;
PIGUET, D ;
BACHMANN, F ;
COSTA, J .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 87 (02) :180-186
[6]   EFFECTS OF LOW-DOSES OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES [J].
ESTEY, EH ;
KURZROCK, R ;
TALPAZ, M ;
MCCREDIE, KB ;
OBRIEN, S ;
KANTARJIAN, HM ;
KEATING, MJ ;
DEISSEROTH, AB ;
GUTTERMAN, JU .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (03) :291-295
[7]   APASTIC ANEMIA AND THE HYPOCELLULAR MYELODYSPLASTIC SYNDROME - HISTOMORPHOLOGICAL, DIAGNOSTIC, AND PROGNOSTIC FEATURES [J].
FOHLMEISTER, I ;
FISCHER, R ;
MODDER, B ;
RISTER, M ;
SCHAEFER, HE .
JOURNAL OF CLINICAL PATHOLOGY, 1985, 38 (11) :1218-1224
[8]  
FRISCH B, 1986, SCAND J HAEMATOL, V36, P21
[9]  
FRISCH B, 1986, SCAND J HAEMATOL, V36, P38
[10]  
FRISCH B, 1990, ATLAS BONE MARROW PA, P67